# US 5,332,758 A · Collagen metabolism ameliorant and its use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,332,758 A
- Document ID: US5332758A
- Status: Granted
- Kind: A
- Application number: 08/004,107
- Filed: 1993-01-13
- Granted: 1994-07-26
- Earliest claimed: 1990-07-13
- Assignees: Kanebo, Ltd.
- Inventors: Masanori Nakata; Shintaro Inoue; Mikio Sotomura; Junsei Taira; Itaru Miyamoto
- Web page: https://patentgrep.com/patent/US5332758A

## CPC

- A61K 8/44: Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K 31/195: having an amino group
- A61Q 7/00: Preparations for affecting hair growth
- A61Q 19/08: Anti-ageing preparations
- A61K 2800/70: Biological properties of the composition as a whole
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61Q: SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS

## Abstract

This invention relates to a collagen metabolism ameliorant containing N-methyl-L-serine as an active ingredient, more particularly, a collagen metabolism ameliorant efficacious against collagen hypometabolism caused by aging or diseases accompanied with an abnormal cumulation of collagen, such as hepatic and pulmonary fibroses, keloid, hypertrophic scar, scleroderma, fibrosis in the scalp, or the like.

## Claims

### Claim 1

A method of ameliorating collagen metabolism in a human patient, said method comprising the step of administering N-methyl-L-serine in a dosage between 0.1 and 1,000 mg to said patient.

### Claim 2

A method of treating a disease associated with an abnormal accumulation of collagen, said method comprising the step of administering N-methyl-L-serine in a dosage between 0.1 and 1,000 mg to a patient afflicted with said disease.

### Claim 3 (depends on 2)

The method of claim 2, wherein said disease is selected from the group consisting of hepatic fibrosis, pulmonary fibrosis, keloid, hypertrophic scar, scleroderm and scalp fibrosis.

### Claim 4 (depends on 2)

The method of claim 2, wherein said disease is associated with an abnormal accumulation of collagen in an organ and is selected from the group consisting of hepatic fibrosis and pulmonary fibrosis, and said N-methyl-L-serine is administered perorally or by injection in a dosage between 30 and 1,000 mg.

### Claim 5 (depends on 3)

The method of claim 3, wherein said disease is associated with an abnormal accumulation of collagen in skin and is selected form the group consisting of keloid, hypertrophic scar, scleroderm and scalp fibrosis, and said N-methyl-L-serine is administered percutaneously in a dosage between 0.1 and 50 mg.